Summary

In the SELECT trial, lenvatinib treatment of patients with radioactive iodine 131–refractory differentiated thyroid cancer was associated with increased thyroid-stimulating hormone levels. An exploratory analysis found that worst postbaseline thyroid-stimulating hormone levels were not associated with differences in overall safety, progression-free survival, overall survival, or overall response rate.